Pacific Biosciences Of California (PACB) EBT (2010 - 2026)

Pacific Biosciences Of California's EBT history runs 17 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• In Q1 2026, EBT rose 98.1% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$127.8 million (up 80.57% YoY), while the FY2025 annual figure was -$546.1 million, down 76.41% from the prior year.
• EBT was -$8.1 million for Q1 2026 at Pacific Biosciences Of California, up from -$40.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $2.7 million in Q4 2024 to a low of -$426.4 million in Q1 2025.
• Historically, EBT has averaged -$88.0 million across 5 years, with a median of -$77.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT soared 103.25% in 2024, then plunged 1594.94% in 2025.
• A 5-year view of EBT shows it stood at -$84.4 million in 2022, then gained by 1.95% to -$82.7 million in 2023, then jumped by 103.25% to $2.7 million in 2024, then sank by 1594.94% to -$40.2 million in 2025, then soared by 79.86% to -$8.1 million in 2026.
• The last three EBT figures came in at -$8.1 million (Q1 2026), -$40.2 million (Q4 2025), and -$37.6 million (Q3 2025), per Business Quant data.